Abstract
ASCO recently published new guidance on systemic therapy for tumor control in well-differentiated metastatic gastrointestinal and pancreatic neuroendocrine tumors in the Journal of Clinical Oncology. A companion Q and A article in the JCO-OP addresses some of the questions that clinicians may face as they implement these recommendations into clinical practice, including the role of somatostatin receptors and observation, definition of terms used within the guideline, considerations related to therapy options for G3 NETs, and future direction in research and treatment. ASCO also plans to address recommendations on the topic of symptom control of GEP-NETs in a forthcoming guideline
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
